Herpes zoster - Èpès Zoster
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Èpès zoster ti anpoul sou kou a ak zepòl
References
Zona, ki te koze pa reaktivasyon viris varisèl zoster ki responsab varisèl la, afekte anviwon 1 milyon moun chak ane nan peyi Etazini, ak yon risk pou tout lavi 30%. Moun ki gen sistèm iminitè febli yo siyifikativman plis tandans devlope zona, ak sentòm tipikman kòmanse ak malèz, maltèt, ak yon lafyèv twò grav, ki te swiv pa sansasyon po etranj kèk jou anvan aparans nan yon gratèl. Gratèl sa a, anjeneral parèt nan yon zòn espesifik nan kò a, pwogrese soti nan ti anpoul klè nan maleng kwout sou yon semèn a dis jou. Tretman rapid ak medikaman antiviral (acyclovir, valacyclovir, or famciclovir) nan lespas 72 èdtan apre kòmansman gratèl la enpòtan anpil. Neuralji postherpetic, yon konplikasyon komen ki karakterize pa doulè pwolonje nan zòn ki afekte a, afekte apeprè youn nan senk pasyan epi li mande pou jesyon kontinyèl ak medikaman tankou gabapentin, pregabalin, oswa sèten depresè, ansanm ak ajan aktualite tankou lidokayin oswa capsaicin. Yo rekòmande vaksinasyon kont viris varisèl zoster la pou adilt ki gen laj 50 an oswa pi wo a pou diminye risk pou yo gen zona.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Herpes zoster gen tandans rive pi souvan nan moun ki gen laj 50 an oswa plis, moun ki gen sistèm iminitè febli, ak moun ki pran medikaman imunosuppressant. Li deklanche pa reyaktivasyon viris varisèl-zoster la, menm viris ki lakòz varisèl la. Sentòm tankou lafyèv, doulè, ak gratèl souvan anvan aparans nan gratèl la karakteristik. Konplikasyon ki pi komen se neuralji pòs-èpètik, ki se doulè nè ki pèsistan apre gratèl la efase. Faktè risk ak konplikasyon ki asosye ak èpès zoster yo varye selon laj, sante iminitè, ak tan inisyasyon tretman an. Vaksinasyon pou moun ki gen laj 60 ak pi wo yo te montre siyifikativman diminye ensidan an nan èpès zoster ak nèralji pòs-èpètik. Kòmanse medikaman antiviral ak soulaje doulè nan lespas 72 èdtan apre aparisyon gratèl la ka diminye gravite ak konplikasyon èpès zoster ak neuralji pòs-èpètik.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Esè klinik yo anvan apwobasyon endike ke vaksen an zoster vivan travay alantou 50 a 70%, pandan y ap vaksen an rekonbinan fè pi byen, sòti nan 90 a 97%. Nan syans reyèl yo, yo sipòte rezilta esè yo, ki montre ke vaksen an vivan an se apeprè 46% efikas, pandan y ap youn nan recombinant se alantou 85%.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
Varisèl, ki rele tou varisèl, rezilta nan premye enfeksyon an ak viris la, tipikman rive pandan anfans oswa adolesans. Yon fwa varisèl la geri, viris la ka rete inaktif (andòmi) nan selil nè imen an pou ane oswa dè dekad, apre sa li ka reaktive. èpès zoster (herpes zoster) rezilta lè viris varisèl andòmi an reaktive. Lè sa a, viris la vwayaje sou kò nè yo nan tèminezon nè ki nan po a, ki pwodui ti anpoul. Pandan yon epidemi èpès zoster (herpes zoster) , ekspoze a viris varisèl yo jwenn nan ti anpoul èpès zoster (herpes zoster) ka lakòz varisèl nan yon moun ki poko gen varisèl.
Faktè risk pou reaktivasyon viris andòmi an gen ladan laj fin vye granmoun, fonksyon iminitè pòv, ak saranpyon kontrakte anvan 18 mwa. Viris varisèl zoster pa menm ak viris èpès senp, byenke tou de fè pati menm fanmi èpèsviris.
Vaksen èpès zoster (herpes zoster) diminye risk pou èpès zoster (herpes zoster) pa 50% a 90%. Li diminye tou pousantaj neuralji postherpetic, epi, si èpès zoster (herpes zoster) rive, gravite li yo. Si èpès zoster (herpes zoster) devlope, medikaman antiviral tankou aciclovir ka diminye gravite a ak dire maladi a si yo kòmanse nan lespas 72 èdtan apre aparans nan gratèl la.
○ Tretman
Si blesi yo pwopaje rapidman, al wè doktè ou pi vit posib pou tretman antiviral.
Yo mande tou de medikaman antiviral ak medikaman nèralji. Ou ta dwe repoze epi sispann bwè alkòl.
#Acyclovir
#Fancyclovir
#Valacyclovir
#Gabapentin
#Pregabalin